Skip to main content
Top
Published in: Annals of Hematology 4/2024

10-07-2023 | Paraneoplastic Syndromes | Review Article

Paraneoplastic syndromes associated with classic Hodgkin lymphoma, a systematic literature review

Authors: Riad El Fakih, Yazeed S. Bajuaifer, Amna Yousaf Shah, Reem Sulaiman, Rawan Almohamady, Ghada ELGohary, Haya S Alothaimeen, Mahmoud Aljurf

Published in: Annals of Hematology | Issue 4/2024

Login to get access

Abstract

PNS are uncommon manifestations of cancer. The current literature about these syndromes in the setting of cHL is disintegrated. A systematic literature review of all published literature was conducted. One hundred twenty-eight patients from 115 publications met the inclusion/exclusion criteria. Eight-five patients were of the NS subtype (66.4%). The most frequent clinical presentation of the PNS was CNS manifestation (25.8%). The majority of patients were diagnosed with the cHL and PNS simultaneously (42.2%). In 33.6% of patients, the lymphoma diagnosis preceded the PNS diagnosis. In 16.4% of patients, the PNS diagnosis preceded the lymphoma diagnosis. The presence of PNS antibodies was reported in 35 patients (27.3%). Age older than 18 was associated with higher prevalence of PNS. The CR rate of the lymphoma was 77.3%. The complete resolution rate of the PNS was 54.7%. Relapse of lymphoma was reported in 13 patients, and recurrence of the PNS upon relapse was reported in 10/13 patients.
Literature
1.
go back to reference Pelosof LC, Gerber DE (2010) Paraneoplastic syndromes: an approach to diagnosis and treatment. In: Mayo Clinic Proceedings, vol 9. Elsevier, pp 838–854 Pelosof LC, Gerber DE (2010) Paraneoplastic syndromes: an approach to diagnosis and treatment. In: Mayo Clinic Proceedings, vol 9. Elsevier, pp 838–854
3.
go back to reference Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F (2013) Encephalitis and antibodies to dipeptidyl-peptidase–like protein-6, a subunit of Kv4. 2 potassium channels. Ann Neurol 73(1):120–128CrossRefPubMed Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F (2013) Encephalitis and antibodies to dipeptidyl-peptidase–like protein-6, a subunit of Kv4. 2 potassium channels. Ann Neurol 73(1):120–128CrossRefPubMed
4.
go back to reference Briani C, Vitaliani R, Grisold W, Honnorat J, Graus F, Antoine J, Bertolini G, Giometto B (2011) Spectrum of paraneoplastic disease associated with lymphoma. Neurology 76(8):705–710CrossRefPubMed Briani C, Vitaliani R, Grisold W, Honnorat J, Graus F, Antoine J, Bertolini G, Giometto B (2011) Spectrum of paraneoplastic disease associated with lymphoma. Neurology 76(8):705–710CrossRefPubMed
5.
go back to reference Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098CrossRefPubMedPubMedCentral Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098CrossRefPubMedPubMedCentral
6.
go back to reference Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K (2012) Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma 53(3):371–380CrossRefPubMed Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K (2012) Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma 53(3):371–380CrossRefPubMed
7.
go back to reference Racanelli V, Prete M, Minoia C, Favoino E, Perosa F (2008) Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7(5):352–358CrossRefPubMed Racanelli V, Prete M, Minoia C, Favoino E, Perosa F (2008) Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7(5):352–358CrossRefPubMed
8.
go back to reference Graus F, Ariño H, Dalmau J (2014) Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood, J Am Soc Hematol 123(21):3230–3238 Graus F, Ariño H, Dalmau J (2014) Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood, J Am Soc Hematol 123(21):3230–3238
9.
go back to reference Graus F, Delattre J, Je A, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren J (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75(8):1135–1140CrossRefPubMedPubMedCentral Graus F, Delattre J, Je A, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren J (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75(8):1135–1140CrossRefPubMedPubMedCentral
10.
go back to reference Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, Rabinovitch R (2008) Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncol 47(5):962–970CrossRefPubMed Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, Rabinovitch R (2008) Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncol 47(5):962–970CrossRefPubMed
11.
go back to reference Hagler KT, Lynch JW Jr (2004) Paraneoplastic manifestations of lymphoma. Clin Lymphoma 5(1):29–36CrossRefPubMed Hagler KT, Lynch JW Jr (2004) Paraneoplastic manifestations of lymphoma. Clin Lymphoma 5(1):29–36CrossRefPubMed
13.
go back to reference Erlij D, Calderón B, Rivera A, Mella C, Valladares X, Roessler E, Rivera MT, Méndez G (2016) Polyarthritis and membranoproliferative glomerulonephritis as paraneoplastic manifestation of Hodgkin’s lymphoma: a case report and literature review. Reumatología Clínica (English Edition) 12(5):282–284CrossRef Erlij D, Calderón B, Rivera A, Mella C, Valladares X, Roessler E, Rivera MT, Méndez G (2016) Polyarthritis and membranoproliferative glomerulonephritis as paraneoplastic manifestation of Hodgkin’s lymphoma: a case report and literature review. Reumatología Clínica (English Edition) 12(5):282–284CrossRef
16.
go back to reference Sfrijan D, Tieranu I, Necula I, Popa L, Balgradean M (2016) Nephrotic syndrome, paraneoplastic syndrome associated to Hodgkin lymphoma. Maedica 11(1):64PubMedPubMedCentral Sfrijan D, Tieranu I, Necula I, Popa L, Balgradean M (2016) Nephrotic syndrome, paraneoplastic syndrome associated to Hodgkin lymphoma. Maedica 11(1):64PubMedPubMedCentral
17.
go back to reference Bernal F, Shams’Ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Smitt PS, Graus F (2003) Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 60(2):230–234CrossRefPubMed Bernal F, Shams’Ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Smitt PS, Graus F (2003) Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 60(2):230–234CrossRefPubMed
18.
go back to reference Hammack J, Kotanides H, Rosenblum M, Posner J (1992) Paraneoplastic cerebellar degeneration: II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology 42(10):1938–1938CrossRefPubMed Hammack J, Kotanides H, Rosenblum M, Posner J (1992) Paraneoplastic cerebellar degeneration: II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology 42(10):1938–1938CrossRefPubMed
20.
go back to reference Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E (1983) Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer 51(10):1934–1936CrossRefPubMed Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E (1983) Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer 51(10):1934–1936CrossRefPubMed
21.
go back to reference Farruggia P, Trizzino A, Maringhini S, Grigoli A, Sapia C, D’Alessandro M, Tropia S, D’Angelo P (2010) Hodgkin lymphoma and nephrotic syndrome in childhood. Indian J Pediatr 77(10):1147–1149CrossRefPubMed Farruggia P, Trizzino A, Maringhini S, Grigoli A, Sapia C, D’Alessandro M, Tropia S, D’Angelo P (2010) Hodgkin lymphoma and nephrotic syndrome in childhood. Indian J Pediatr 77(10):1147–1149CrossRefPubMed
22.
go back to reference Christensen PB, Gregersen H, Almasi C (2021) Anti-Tr/DNER antibody paraneoplastic cerebellar degeneration preceding a very late relapse of Hodgkin Lymphoma after 12 years. Cerebellum Ataxias 8(1):1–4CrossRef Christensen PB, Gregersen H, Almasi C (2021) Anti-Tr/DNER antibody paraneoplastic cerebellar degeneration preceding a very late relapse of Hodgkin Lymphoma after 12 years. Cerebellum Ataxias 8(1):1–4CrossRef
23.
go back to reference de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71(6):815–824CrossRefPubMed de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71(6):815–824CrossRefPubMed
24.
go back to reference Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799. https://doi.org/10.1016/s0140-6736(11)61940-5CrossRefPubMed Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799. https://​doi.​org/​10.​1016/​s0140-6736(11)61940-5CrossRefPubMed
25.
go back to reference Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554. https://doi.org/10.1200/jco.2008.19.8820CrossRefPubMed Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554. https://​doi.​org/​10.​1200/​jco.​2008.​19.​8820CrossRefPubMed
26.
go back to reference Greene M, Lai Y, Baella N, Dalmau J, Lancaster E (2014) Antibodies to delta/notch-like epidermal growth factor–related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 71(8):1003–1008CrossRefPubMedPubMedCentral Greene M, Lai Y, Baella N, Dalmau J, Lancaster E (2014) Antibodies to delta/notch-like epidermal growth factor–related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 71(8):1003–1008CrossRefPubMedPubMedCentral
Metadata
Title
Paraneoplastic syndromes associated with classic Hodgkin lymphoma, a systematic literature review
Authors
Riad El Fakih
Yazeed S. Bajuaifer
Amna Yousaf Shah
Reem Sulaiman
Rawan Almohamady
Ghada ELGohary
Haya S Alothaimeen
Mahmoud Aljurf
Publication date
10-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05357-5

Other articles of this Issue 4/2024

Annals of Hematology 4/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.